Bionano Stock Today

BNGO
 Stock
  

USD 1.83  0.04  2.14%   

Market Performance
5 of 100
Odds Of Distress
Less than 6
Bionano Genomics is selling for 1.83 as of the 2nd of October 2022. This is a -2.14 percent down since the beginning of the trading day. The stock's open price was 1.87. Bionano Genomics has only a 6 % chance of going through financial distress over the next few years but had a somewhat modest performance during the last 90 days. Equity ratings for Bionano Genomics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of October 2020 and ending today, the 2nd of October 2022. Click here to learn more.
Bionano Genomics, Inc. provides genome analysis software solutions. The company was founded in 2003 and is headquartered in San Diego, California. Bionano Genomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 290.14 M outstanding shares of which 44.17 M shares are currently shorted by private and institutional investors with about 7.55 trading days to cover. More on Bionano Genomics

Moving together with Bionano Genomics

+0.79AAgilent Technologies Fiscal Year End 28th of November 2022 PairCorr
+0.73JPMJP Morgan Chase Fiscal Year End 13th of January 2023 PairCorr
+0.93DISWalt Disney Fiscal Year End 9th of November 2022 PairCorr
+0.64WMTWalmart TrendingPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Bionano Genomics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Bionano Genomics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Bionano Genomics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Bionano Genomics is way too risky over 90 days horizon
Bionano Genomics may become a speculative penny stock
Bionano Genomics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 20.51 M. Net Loss for the year was (92.44 M) with profit before overhead, payroll, taxes, and interest of 3.87 M.
Bionano Genomics currently holds about 216.47 M in cash with (90.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75.
Latest headline from www.benzinga.com: If You Invested 1,000 In BioNano Stock At Its COVID-19 Pandemic Low, Heres How Much Youd Have N - Benzinga
President CEO, DirectorErik Holmlin
Average Analyst Recommendation
Analysts covering Bionano Genomics report their recommendations after researching Bionano Genomics' financial statements, talking to executives and customers, or listening in on Bionano Genomics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Bionano Genomics. The Bionano consensus assessment is calculated by taking the average forecast from all of the analysts covering Bionano Genomics.
Strong Buy4 Opinions
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Bionano Genomics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Bionano Genomics (BNGO) is traded on NASDAQ Exchange in USA and employs 299 people. The company currently falls under 'Small-Cap' category with current market capitalization of 681.83 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bionano Genomics's market, we take the total number of its shares issued and multiply it by Bionano Genomics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Bionano Genomics conducts business under Healthcare sector and is part of Diagnostics & Research industry. The entity has 290.14 M outstanding shares of which 44.17 M shares are currently shorted by private and institutional investors with about 7.55 trading days to cover. Bionano Genomics currently holds about 216.47 M in cash with (90.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75.
Check Bionano Genomics Probability Of Bankruptcy
Ownership
Bionano Genomics retains a total of 290.14 Million outstanding shares. Almost 72.0 percent of Bionano Genomics outstanding shares are held by regular investors with 1.92 (percent) owned by insiders and only 25.84 % by other corporate entities. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Bionano Ownership Details

Bionano Stock Price Odds Analysis

Proceeding from a normal probability distribution, the odds of Bionano Genomics jumping above the current price in 90 days from now is about 73.77%. The Bionano Genomics probability density function shows the probability of Bionano Genomics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 3.1563 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Bionano Genomics will likely underperform. Additionally, the company has an alpha of 0.976, implying that it can generate a 0.98 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 1.83HorizonTargetOdds Above 1.83
26.16%90 days
 1.83 
73.77%
Based on a normal probability distribution, the odds of Bionano Genomics to move above the current price in 90 days from now is about 73.77 (This Bionano Genomics probability density function shows the probability of Bionano Stock to fall within a particular range of prices over 90 days) .

Bionano Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Bionano Genomics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bionano Genomics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bionano Genomics' value.
InstituionSecurity TypeTotal SharesValue
Blackrock IncCommon Shares21 M29 M
Vanguard Group IncCommon Shares15.6 M21.6 M
View Bionano Genomics Diagnostics

Bionano Genomics Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Bionano Genomics market risk premium is the additional return an investor will receive from holding Bionano Genomics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Bionano Genomics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Bionano Genomics' alpha and beta are two of the key measurements used to evaluate Bionano Genomics' performance over the market, the standard measures of volatility play an important role as well.

Bionano Stock Against Markets

Picking the right benchmark for Bionano Genomics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Bionano Genomics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Bionano Genomics is critical whether you are bullish or bearish towards Bionano Genomics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bionano Genomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Positions Ratings Now

   

Positions Ratings

Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Bionano Genomics Corporate Directors

Bionano Genomics corporate directors refer to members of a Bionano Genomics board of directors. The board of directors generally takes responsibility for the Bionano Genomics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Bionano Genomics' board members must vote for the resolution. The Bionano Genomics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Darren Cai - Independent DirectorProfile
Albert Luderer - Independent DirectorProfile
Kristiina Vuori - Independent DirectorProfile
Christopher Twomey - Independent DirectorProfile

Invested in Bionano Genomics?

The danger of trading Bionano Genomics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Bionano Genomics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Bionano Genomics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Bionano Genomics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. Note that the Bionano Genomics information on this page should be used as a complementary analysis to other Bionano Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for Bionano Stock analysis

When running Bionano Genomics price analysis, check to measure Bionano Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionano Genomics is operating at the current time. Most of Bionano Genomics' value examination focuses on studying past and present price action to predict the probability of Bionano Genomics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bionano Genomics' price. Additionally, you may evaluate how the addition of Bionano Genomics to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Is Bionano Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine Bionano Genomics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.